The Lancet, Volume 373, Issue 9679, Pages 1949 – 1957, 6 June 2009
doi:10.1016/S0140-6736(09)60691-7: Munoz, et al
Background:
Although the peak incidence of human papillomavirus (HPV) infection occurs in most populations within 5—10 years of first sexual experience, all women remain at risk for acquisition of HPV infections. We tested the safety, immunogenicity, and efficacy of the quadrivalent HPV (types 6, 11, 16, 18) L1 virus-like-particle vaccine in women aged 24—45 years.
